Evidence map›Paper›PMID 38675599›Full record

ArticleMolecules (Basel, Switzerland)2024

Discovery of Dolutegravir Derivative against Liver Cancer via Inducing Autophagy and DNA Damage.

Xixi Hou, Dong Yan, Ziyuan Wu, Longfei Mao, Huili Wang, Yajie Guo, Jianxue Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Assessment of the Biological Properties ofMolecules (Basel, Switzerland) · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xixi HouThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.
Dong YanCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, 263 Kaiyuan Road, Luoyang 471003, China.
Ziyuan WuCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, 263 Kaiyuan Road, Luoyang 471003, China.
Longfei MaoCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, 263 Kaiyuan Road, Luoyang 471003, China.
Huili WangUniversity of North Carolina Hospitals, 101 Manning Dr, Chapel Hill, Orange County, NC 27599, USA.
Yajie GuoDepartment of Emergency, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China.
Jianxue YangThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We introduced a terminal alkyne into the core structure of dolutegravir, resulting in the synthesis of 34 novel dolutegravir-1,2,3-triazole compounds through click chemistry. These compounds exhibited remarkable inhibitory activities against two hepatocellular carcinoma cell lines, Huh7 and HepG2. Notably, compounds

Indexed as

Antineoplastic AgentsApoptosisAutophagyDNA DamageHeterocyclic Compounds, 3-RingLiver NeoplasmsOxazinesPiperazinesPyridonesReactive Oxygen SpeciesCarcinoma, HepatocellularCell Line, TumorCell ProliferationDolutegravirDrug DiscoveryHep G2 CellsAntineoplastic AgentsDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesReactive Oxygen Species1,2,3-triazoleanti-tumordolutegravirhepatocellular carcinoma cell lines DNA damage

Identifiers

PMID38675599
PMCPMC11052077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.